Scientific deep-dive
Does Contrave Reduce Cravings? What a 2026 Pooled Analysis Found
A 2026 pooled post hoc analysis of phase 3 completers found Contrave improved craving control and some food cravings more than placebo. Here is what the numbers show, why the completer design matters, and what the label says.
Contrave appears to reduce some food cravings more than placebo, but the strongest data come from a post hoc analysis limited to people who finished treatment. In that 2026 pooled analysis of 1,967 phase 3 completers, naltrexone-bupropion improved craving control by an estimated treatment difference of 2.68 (95% CI 0.85 to 4.50) on the Control of Eating Questionnaire.[1] Cravings were also lower for savory foods and for high-fat foods, while the abstract reports no sweet-craving result.[1]
About this article
This page isolates the craving outcomes. For the drug’s mechanism and overall weight results, see our Contrave evidence review. The abstract of the 2026 analysis doesn’t give full subscale tables or scoring ranges.
What the pooled analysis measured
Kushner and colleagues, writing in Obesity Research & Clinical Practice, pooled four phase 3 trials and compared 1,206 patients on extended-release naltrexone-bupropion with 761 on placebo at weeks 8, 16, 28, and 56.[1] Two questionnaires captured cravings: the Control of Eating Questionnaire (CoEQ) and the Food Craving Inventory (FCI).[1] The trial registration numbers match the four COR trials: COR-I, COR-II, COR-BMOD, and COR-Diabetes.[1][2]
- Craving control (CoEQ): estimated treatment difference 2.68 (95% CI 0.85 to 4.50).[1]
- Positive mood (CoEQ): 1.35 (95% CI 0.47 to 2.23).[1]
- Cravings for savory foods (CoEQ): −1.81 (95% CI −3.32 to −0.30).[1]
- Cravings for high fats (FCI): −0.65 (95% CI −0.98 to −0.32).[1]
- Cravings for fast-food fats (FCI): −0.18 (95% CI −0.39 to −0.03).[1]
Those intervals exclude zero, so the differences are statistically distinguishable from placebo. Whether a patient would notice them is harder to judge. The abstract doesn’t state the score ranges, the timepoint for each estimate, or a threshold for a meaningful change, and it doesn’t report a result for sweet cravings, even though the CoEQ has a sweet subscale.[1][2] A reader looking for help with sugar specifically can’t get an answer from this abstract.
Baseline cravings did not predict who lost more weight on the drug compared with placebo: the week 56 weight change “did not differ by baseline CoEQ or FCI scores.”[1] This cuts against the common idea that Contrave works best, or only, in people with intense cravings.
Why the completer design matters
The analysis was on-treatment and included only people who completed a trial.[1] That estimand asks what happened among those who stayed on treatment. It doesn’t tell a new patient what to expect on starting the drug, because people who stop early, whether from nausea or from disappointing results, drop out of the picture. The FDA label counts 4,536 patients randomized to Contrave or placebo across these four trials, and fewer than half are in the 1,967 analyzed here.[10][1]
Weight results show the effect of this selection. Completers in the pooled analysis lost 9.5% (±8.0%) on naltrexone-bupropion and 2.7% (±6.9%) on placebo through 56 weeks.[1] The original trials, which used broader populations, reported less. COR-BMOD gives the clearest demonstration because it published three versions of the same result: 11.5% vs 7.3% in completers, 9.3% vs 5.1% in its modified intent-to-treat group, and 7.8% vs 4.9% among all randomized participants.[5]
| Source | Population as reported | Naltrexone-bupropion | Placebo |
|---|---|---|---|
| Kushner 2026, pooled | On-treatment completers | −9.5% | −2.7% |
| COR-I | Randomized, with a post-baseline weight on study drug; 32 mg arm | −6.1% | −1.3% |
| COR-II | As stated in the abstract, week 56 | −6.4% | −1.2% |
| COR-BMOD | Modified intent-to-treat, with intensive behavior modification | −9.3% | −5.1% |
| COR-Diabetes | Modified intent-to-treat, type 2 diabetes | −5.0% | −1.8% |
The trial figures above come from the published COR-I, COR-II, COR-BMOD, and COR-Diabetes abstracts.[3][4][5][6] Dropout was substantial: in COR-I, 50% of participants completed 56 weeks of treatment.[3] Because these estimands differ, the rows can’t be compared as if they measured one effect.
Post hoc means the analysis was run after the trials ended and was not the question they were designed to answer. Its record also shows industry ties: all six authors disclose advisory or consulting relationships with Currax Pharmaceuticals, the distributor named on the Contrave label.[1][10]
Does better craving control lead to more weight loss?
An earlier analysis of the same four trials looked at this directly. Dalton and colleagues, using data from Orexigen, the company that conducted the trials, found that people whose craving control improved most by week 8 lost more weight by week 56.[2] The lowest early responders lost about 3 to 4% less weight than the highest responders.[2] Two authors were Orexigen employees and stockholders.[2]
Two details limit the conclusion. The same pattern appeared in placebo patients as well as those on the drug, so early craving improvement may mark who does well in a weight program generally rather than a drug-specific pathway.[2] And the contribution was described as small, explaining 5% of the variance in BMI change.[2] The study is an association among completers, so it can’t show that reduced cravings caused the weight loss. The authors suggested early craving control might work as a marker for identifying people who need extra support, which remains a proposal to test.[2]
Brain imaging and laboratory evidence
Small imaging studies offer a possible mechanism. In 40 women given naltrexone-bupropion or placebo for 4 weeks, the drug blunted hypothalamic activation in response to food cues while increasing activation in regions tied to inhibitory control and internal awareness.[7] In a separate study of 36 healthy women, also over 4 weeks, changes in brain connectivity correlated with craving control scores (r = 0.519, p = 0.039).[8] The lead author of that study reported lecture fees and research funding from Orexigen.[8] These scans are short-term and involved women only, so they can suggest how the drug acts but can’t predict how an individual’s cravings will change.
A 2026 human laboratory study of 50 people with binge-eating disorder, run within a 12-week randomized trial, adds a behavioral test. Naltrexone-bupropion didn’t change the decision to eat, but it reduced calories consumed.[9] Craving for preferred high-calorie sweet snacks and hunger ratings fell at 6 weeks, and that reduction was not seen at 12 weeks.[9] That fade deserves attention given that the pooled analysis spans a year, though the populations differ. Binge-eating disorder is not an indication on the Contrave label.[10]
How this compares with GLP-1 drugs
People often ask whether Contrave beats a GLP-1 for cravings. We found no head-to-head craving trial in this review, so any ranking would be speculation. Our review of GLP-1 drugs and sugar cravings covers that literature separately, and scores from different trials and questionnaires shouldn’t be set side by side.
What the label says, and what to raise with a prescriber
The Contrave label is built around weight. It indicates the drug “to reduce excess body weight and maintain weight reduction long term” alongside diet and activity in eligible adults, and the word craving doesn’t appear in the version revised in November 2025.[10] Its stopping rule is also about weight: response “should be evaluated after 12 weeks at the maintenance dosage,” and the label directs discontinuation for patients who have not lost at least 5% of baseline body weight.[10] Feeling fewer cravings without that weight change doesn’t meet the label’s test for continuing.
Some of the patients most interested in craving control are the ones who need the closest screening. The label contraindicates Contrave in bulimia or anorexia nervosa because of seizure risk, and in seizure disorder, uncontrolled hypertension, and chronic opioid use.[10] It carries a boxed warning on suicidal thoughts and behaviors, and it says the drug “can cause an increase in systolic and/or diastolic blood pressure as well as an increase in resting heart rate.”[10] Our Contrave side effects guide covers these in more detail.
- Describe your eating pattern accurately, including any binge eating, purging, or restriction, since the answer can change whether the drug is an option.
- List every medicine, especially opioids and other bupropion products.
- Ask how your blood pressure and pulse will be monitored, and when you will review progress at the 12-week point.
- Tell your prescriber if cravings return or mood changes while you are taking it.
Frequently Asked Questions
References
- 1.Kushner RF, Iceta S, Tronieri JS, Still CD, Fitch A, Apovian CM. Fixed-dose, extended-release combination of naltrexone and bupropion reduces craving and body weight: A pooled post hoc analysis. Obes Res Clin Pract. 2026. PMID: 42642275.
- 2.Dalton M, Finlayson G, Walsh B, Halseth AE, Duarte C, Blundell JE. Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample. Int J Obes (Lond). 2017. PMID: 28373674.
- 3.Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010. PMID: 20673995.
- 4.Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E; COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013. PMID: 23408728.
- 5.Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011. PMID: 20559296.
- 6.Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K; COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013. PMID: 24144653.
- 7.Wang GJ, Tomasi D, Volkow ND, Wang R, Telang F, Caparelli EC, Dunayevich E. Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. Int J Obes (Lond). 2014. PMID: 23924756.
- 8.Wang GJ, Zhao J, Tomasi D, Kojori ES, Wang R, Wiers CE, Caparelli EC, Volkow ND. Effect of combined naltrexone and bupropion therapy on the brain's functional connectivity. Int J Obes (Lond). 2018. PMID: 29535451.
- 9.McKee SA, Lydecker JA, Pittman B, Jastreboff AM, DiLeone RJ, Lavery M, Grilo CM. Naltrexone/bupropion for binge-eating disorder: A human laboratory investigation of mechanisms. Drug Alcohol Depend Rep. 2026. PMID: 41867954.
- 10.Nalpropion Pharmaceuticals LLC. CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets, prescribing information. DailyMed, National Library of Medicine. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b
Related research
Naltrexone for Weight Loss + How Contrave Actually Works: Evidence Review
Naltrexone alone is not FDA-approved for weight loss. Contrave (naltrexone plus bupropion) is, and produced -6.1% mean weight loss at 56 weeks in the COR-I trial. How it works, how it compares with Wegovy and Zepbound across trials, and who it suits.
14 min read
Contrave Side Effects (2026): What's Common, What's Serious & How to Manage Them
Contrave (naltrexone/bupropion), which is not a GLP-1, most often causes nausea, constipation, headache and insomnia. Serious FDA-label risks include a boxed warning for suicidal thoughts, seizures, higher blood pressure and liver injury.
11 min read
Wellbutrin XL for Weight Loss: How Fast and How Much? (Evidence Review)
Wellbutrin XL is not FDA-approved for weight loss, but bupropion is the one antidepressant tied to weight loss rather than gain. Off-label trials showed about 4.4 kg at 26 weeks. Boxed warning for suicidality under age 25; not for seizure disorders or eating disorders.
13 min read
Does Bupropion Cause Weight Loss? Honest Evidence Review
Bupropion causes modest weight loss but is not FDA-approved for obesity on its own. In Anderson 2002, completers on 300 or 400 mg/day plus diet counseling lost 7.2% and 10.1% at 24 weeks vs 5.0% on placebo. Contrave, the approved combination, gave 6.1% at 56 weeks.
12 min read
Artificial Sweeteners on a GLP-1: Help or Hurt?
Do sucralose, stevia, and sugar alcohols help or hurt on a GLP-1? Evidence on calories, GI symptoms, cravings, microbiome, and the erythritol heart signal.
9 min read
Can You Drink Alcohol on a GLP-1? Safety & Cravings Evidence
No FDA label forbids drinking on semaglutide, but GLP-1s lower alcohol tolerance and raise hypoglycemia risk in diabetes, and they appear to reduce alcohol cravings. Practical drinking guidance and the red flags that mean stop.
10 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →Pricing Compare
Get started →Pricing Compare
Get started →Pricing Compare
Get started →